Since CXCR4 activation has been shown to mediate downstream MAPK and AKT activity [28, 29], we examined if ibrutinib could inhibit SDF1 induced MAPK and AKT signalling in primary AML blast. Here, CXCL12 is linked to acute myeloid leukemia.